《美國股市》道指倒跌461點或1.3% 盤中曾升逾500點
美股先升後倒跌,市場消化美聯儲主席鮑威爾的言論後反彈,但美國確診首宗新冠變種Omicron個案觸發尾段急挫。道指高開195點後升幅擴大,上午中段曾升520點見35,004點,尾市急轉直下,收市前曾跌476點見34,006點。
道瓊斯工業平均指數跌461.68點或1.3%,收報34,022.04點。
標準普爾500指數跌53.96點或1.2%,收報4,513.04點。
納斯達克指數跌283.64點或1.8%,收報15,254.05點。
Salesforce(CRM.US)跌11.7%,爲跌幅最大道指成分股。波音公司(BA.US)跌4.9%,陶氏(DOW.US)跌4%,沃爾瑪(WMT.US)及Walgreens(WBA.US)各跌2.5%及2.4%。強生(JNJ.US)及寶潔(PG.US)各升1.4%及1.3%,爲升幅最大道指成分股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.